Cleerly Announces FDA Clearance of Latest Version of Cleerly LABS
The clearance includes Cleerly PLAQUE, an updated plaque algorithm powered by CONFIRM2 data
Cleerly's TRANSFORM Trial Sends a Mobile CT Scanner Across the South to Reach Patients in Underserved Communities
Operated with Clear Heart and Lung, the unit enables patients in communities without cardiac CT to join TRANSFORM, a trial testing whether treatment...
Cleerly Announces New Findings on How AI-QCT Plaque Measurements Relate to Long-Term Cardiovascular Risk
New ESC Congress 2026 data, published simultaneously in EJNMMI, show that AI-quantified plaque burden was independently associated with...
Cleerly and Allelica Partner to Launch a Polygenic Risk Score Test for Coronary Artery Disease
The Cleerly Polygenic Cardiovascular Risk Score Test, powered by Allelica’s proprietary multi-ancestry PRS technology, gives physicians a new option...
